Highlights from

AAN 2019

American Academy of Neurology annual meeting

Philadelphia, USA 4-10 May 2019

Mesenchymal stem cells in a proof-of-concept study

Preliminary findings from an ongoing small proof-of-concept study suggested that infusions of allogeneic mesenchymal stem cells may be safe and well tolerated in subjects with mild to moderate idiopathic Parkinson’s disease [1].

Participants are 20 subjects 45-78 years of age, with OFF state Hoehn and Yahr classification ≤3. Each dose cohort consists of 5 study subjects that received 1 of 4 doses of mesenchymal stem cells: 1, 3, 6, or 10 x106 mesenchymal stem cells/kg of body weight. The primary outcome is safety, defined as the absence of transfusion reactions, adverse events or organ damage.

There were no adverse reactions in the first 24 hours. In subsequent follow-up, the most common side effects were hypertension, arthralgia, and nausea (27% for each), mild and transient in all cases. The first 14 patients sustained a reduction in Unified Parkinson Disease Rating Scale (UPDRS)-III motor score (OFF state) after 12 weeks. The researchers will complete the study to identify the optimal dose that is well-tolerated and associated with improvement in cognition, motor function, and disability.

  1. Schiess M, et al. AAN 2019, S16.008.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.